| abstract |
The invention discloses a novel antineoplastic drug, which is substantially composed ofnthe Chinese medicinal herbs: Panax ginsing, Poria cocos, Atractylodes macrocephala, Angelicnsinensis, Astragalus membranaceus, Curcuma zedoaria, Scutellaria baicalensis, Coptisnchinenisis, Glycyrrhiza uralenisis, Crataegus pinatifida, Hordeum vulgare, Schisandranchinensis, Hedyotis diffusa, Ophiophogon japonicus, and Lobelia chinesis lour. It is has beennused clinically for more than 20 years, including 15 years in China and 5 years in Israel.nThousands of tumor patients have taken the antineoplastic drug of the present invention withnthe effective rate of 69.7% and that of 84.3% in combination with radiotherapy ornchemotherapy. The clinical and experimental results showed that the antineoplastic drug cannincrease immunity of the organism, inhibit tumor cells and reverse tumor cells to normal state;nmake the patients sedative, and improve blood circulation in order to suppress the growth andnmetastasis of tumor; increase the sensitivity to radiotherapy and chemotherapy and reduce thentoxic and adverse effects of radiotherapy and chemotherapy; improve sleeping, increasenappetite, alleviate pain, and protect the function of liver, kidney and ovary; and increase thennumber of leukocyte and hemoglobin reduced by radiotherapy and chemotherapy. It can alsonenhance the antitumor ability of organism, prevent the relapse of tumor, improve the tumornpatients' quality of life and prevent tumorigenesis. The animal trials conducted in the Tel-AvivnUniversity of Israel proved that the antineoplastic drug could increase NK Cells' activity,nreduce and prevent metastasis of tumor under stress condition. |